Moderna jumps as vaccine shows benefit in head and neck cancer in early study

Not classified

[…] Reuters

9 April 2024 at 5:26 pm·1-min read

(Reuters) -Moderna shares rose 8% to a three-month high on Tuesday after the company’s individualized cancer vaccine developed with Merck showed positive response in an early-stage trial in patients with a type o […]

Back to news